Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001231919-23-000039
Filing Date
2023-06-01
Accepted
2023-06-01 21:25:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3200
  Complete submission text file 0001231919-23-000039.txt   4625
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39536 | Film No.: 23986577
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247
Business Address
McAuliffe Sean (Reporting) CIK: 0001979693 (see all company filings)

Type: 144